A multicentre open-label phase I/Ib trial of melanoma-specific peptide vaccination (UniCanVax) combined with nivolumab in checkpoint blockade-refractory stage III/IV melanoma
Sponsor: Humanitas Mirasole S.p.A.
Phase: 1
Disease: Metastatic melanoma, Unresectable stage III melanoma, Immune checkpoint inhibitor-refractory melanoma
EU trial number: 2025-524486-25-00
Population: Adult patients with metastatic or unresectable stage III/IV melanoma refractory to prior immune checkpoint blockade, enrolled in an Italian multicentre open-label phase I/Ib trial testing UniCanVax melanoma peptide vaccination plus anti-PD-1 nivolumab.
Register Investigator Interest
Interested in offering this trial to suitable patients?